| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 17% YoY growth, hitting 450 crore, primarily organic volume growth. |
|---|---|
| Margins | EBITDA margin expanded 210 bps to 25.2% due to efficiency. |
| Demand visibility | Strong structural shift toward organized diagnostics in smaller towns. |
| Management confidence | High; explicitly stating they exceeded guided revenue and margin targets. |
Growth
Revenue grew 17% YoY, primarily driven by a 10% increase in patient volumes rather than price hikes.
Outlook
Management guides for 14-15% revenue growth and 27-28% EBITDA margins over the next two years.
Risks
Potential margin dilution from aggressive tier-2/3 expansion and dependence on volatile seasonal illness cycles.
Last quarter's promises, checked
Delivered
- Guided 12-13% organic revenue growth → delivered 13.7% (= BEAT)
- Commitment to move Core Diagnostics to high-single-digit EBITDA → delivered high-single-digit (= BEAT)
- Guided organic revenue margins to pre-COVID levels (~26%) → delivered 25.9% (= BEAT)
Partly delivered
- Guided 3-year EBITDA margin target 27-28% → delivered 25.4% Group / 27.2% Organic Q4 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹541.45
- Market cap
- ₹11,233 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 55.7×Sector 53.1×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Merger & Restructuring Worth ₹1.25 Cr
Metropolis Healthcare transferred its External Quality Assessment Services Division to subsidiary MQSPL for ₹1.25 Crore. The transfer was executed via a slump sale.
- Value
- ₹1.25 Cr
Metropolis Healthcare Merger & Restructuring Worth ₹0.01 Cr
Metropolis Healthcare's subsidiary, MQSPL, will issue 10,000 Optionally Convertible Redeemable Preference Shares (OCRPS) to Dr. Puneet Kumar Nigam. Post-conversion, MQSPL will remain a subsidiary.
- Value
- ₹0.01 Cr
Metropolis Healthcare Annual General Meeting
Metropolis Healthcare held its 26th Annual General Meeting on August 18, 2026. Shareholders reviewed financial statements and confirmed previous interim dividend payments.